1)Huhn M, et al.: Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet, 394: 939-951, 2019.
2)Kishi T, et al.: Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. Mol Psychiatry, 27: 1136-1144, 2022.
3)Bahji A, et al.: Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis. J Affect Disord, 269: 154-184, 2020.
4)Kadakia A, et al.: Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis. BMC Psychiatry, 21: 249, 2021.
5)Schneider-Thoma J, et al.: Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases. Lancet, 407: 876-891, 2026.
6)Leucht S, et al.: Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis. World Psychiatry, 22: 315-324, 2023.
7)Ostuzzi G, et al.: Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry, 21: 295-307, 2022.
8)Kishi T, et al.: Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials. Mol Psychiatry, 26: 4146-4157, 2021.
9)Zhang ZX, et al.: Clinical outcomes of recommended active pharmacotherapy agents from NICE guideline for post-traumatic stress disorder: Network meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry, 125: 110754, 2023.
10)Pillinger T, et al.: Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry, 7: 64-77, 2020.
11)Montastruc F, et al.: Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase. Eur Neuropsychopharmacol, 25: 1556-65, 2015.
12)Olten B, Bloch MH.: Meta regression: Relationship between antipsychotic receptor binding profiles and side-effects. Prog Neuropsychopharmacol Biol Psychiatry, 84: 272-281, 2018.
13)Grajales D, et al.: Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor. Cells, 8: 1336, 2019.
14)Carnovale C, et al.: Association between the glyco-metabolic adverse effects of antipsychotic drugs and their chemical and pharmacological profile: a network meta-analysis and regression. Psychol Med, 24: 1-13, 2021.
15)Wu H, et al.: Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials. Schizophr Bull, 48: 643-654, 2021.
16)Sabé M, et al.: Comparative Effects of 11 Antipsychotics on Weight Gain and Metabolic Function in Patients With Acute Schizophrenia: A Dose-Response Meta-Analysis. J Clin Psychiatry, 84: 22r14490, 2023.
17)Brunner E, et al.: Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacol Toxicol, 14: 38, 2013.
18)Uguz F.: Second-Generation Antipsychotics During the Lactation Period: A Comparative Systematic Review on Infant Safety. J Clin Psychopharmacol, 36: 244-52, 2016.